AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B
AusperBio has announced the completion of the first cohort dosing in a Phase 1 clinical trial evaluating AHB–137 in adult healthy volunteers and chronic hepatitis B (CHB) patients in New Zealand. AHB-137 is a potential best-in-class, highly potent, pan-genotypic antisense oligonucleotide (ASO) targeting all HBV RNA for the treatment of CHB patients. AHB-137 has been well-tolerated in all human subjects in the first cohort.
“We are thrilled to initiate the first-in-human dosing of AHB-137 in New Zealand. ASO drug targeting HBsAg production has demonstrated great promise to become a cornerstone therapy to achieve functional cure of CHB. AHB-137 has shown best-in-class activity in reducing HBsAg across multiple preclinical models,” said Dr. Guofeng Cheng, CEO and co-founder of AusperBio. “Over 250 million people are infected with HBV globally and CHB is a difficult to cure viral infection disease that can lead to liver cirrhosis and cancer. Current standard of care can suppress HBV replication, but the cure rate is low. There is a great need to develop safe and finite therapies for HBV cure. AHB-137 has the potential to transform the treatment of CHB patients.”
“The completion of the first cohort dosing of AHB-137 is a significant achievement for AusperBio,” said Dr. Chris Yang, CSO and co-founder of AusperBio. “We are proud of the progress AusperBio has made over the past three years. We are looking forward to advancing additional HBV cure candidates into clinic studies in 2023 for combination therapies and leveraging the potential of our proprietary and potent ASO platform to expand into non-viral targets in and outside the liver.”
The Phase 1 clinical trial is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics of AHB-137 in healthy volunteers and initial efficacy in CHB patients (clinicaltrials.gov # NCT05717686). AHB-137 can trigger the degradation of all HBV RNA and has demonstrated potent reduction of HBsAg with favorable safety profile in preclinical studies. The detailed preclinical profiles of AHB-137 have been submitted for two presentations at an upcoming scientific congress in June.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more